Compare VFF & QNCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VFF | QNCX |
|---|---|---|
| Founded | 1989 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 357.1M | 17.5M |
| IPO Year | 2013 | 2019 |
| Metric | VFF | QNCX |
|---|---|---|
| Price | $2.71 | $28.06 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 8 |
| Target Price | $5.83 | ★ $75.43 |
| AVG Volume (30 Days) | ★ 695.8K | 14.4K |
| Earning Date | 11-09-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 184.38 | N/A |
| EPS | ★ 0.08 | N/A |
| Revenue | ★ $215,937,000.00 | N/A |
| Revenue This Year | $12.34 | N/A |
| Revenue Next Year | $20.22 | N/A |
| P/E Ratio | $35.88 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.81 | $0.08 |
| 52 Week High | $4.99 | $35.41 |
| Indicator | VFF | QNCX |
|---|---|---|
| Relative Strength Index (RSI) | 42.28 | 45.21 |
| Support Level | $2.49 | $25.78 |
| Resistance Level | $3.18 | $34.58 |
| Average True Range (ATR) | 0.11 | 2.51 |
| MACD | -0.04 | -0.17 |
| Stochastic Oscillator | 0.00 | 35.97 |
Village Farms International Inc owns and operates intensive agricultural greenhouse facilities in British Columbia and Texas, where it produces, markets and sells tomatoes, bell peppers and cucumbers. Its wholly owned subsidiary, Pure Sunfarms, is a vertically integrated licensed producer and supplier of cannabis products sold to other licensed providers and provincial governments across Canada and internationally. The Company's wholly owned subsidiary, Balanced Health, develops and sells, cannabidiol (CBD) based products including ingestible, edible and topical applications. The operating segments of the Company are VF Fresh (Produce), Cannabis Canada, Cannabis U.S., Clean Energy, and Cannabis - Netherlands. The company makes majority of its revenue from the Cannabis Canada segment.
Quince Therapeutics Inc is a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases. Its proprietary AIDE technology is an inventive drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells. Its Phase 3 asset, eDSP, leverages the AIDE technology to encapsulate DSP into a patient's own red blood cells, and is targeted to treat a rare pediatric neurodegenerative disease, A-T.